QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

First published online 29 March 2005
doi: 10.1242/jcs.02308

This Article Figures Only Full Text Full Text (PDF) Supplementary Material All Versions of this Article: jcs.02308v1 118/8/1663    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barros, J. C. Articles by Marshall, C. J. Search for Related Content PubMed PubMed Citation Articles by Barros, J. C. Articles by Marshall, C. J.

Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton

Cancer Research UK Centre for Cell and Molecular Biology, Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK

^* Corresponding author (e-mail: chris.marshall{at}icr.ac.uk)

Accepted 3 February 2005

Oncogenic transformation often leads to the disruption of the actin cytoskeleton. Activation of the classical Ras-Raf-MEK1/2-ERK1/2 signalling cascade has been implicated in the effects of oncogenes such as Ras and Src on the cytoskeleton. Many of the studies of the effects of oncogenes on the cytoskeleton have made use of chemical inhibitors of MEK1/2 but it is now clear that these inhibitors also inactivate MEK5 in the MEK5-ERK5 MAP kinase pathway raising the possibility that this pathway may also be involved in oncogenic transformation. We therefore investigated whether activation of ERK5 can lead to disruption of the actin cytoskeleton. We show that activation of ERK5 can lead to loss of actin stress fibres, but by a distinct mechanism to ERK1/2. We demonstrate that ERK5 is activated by oncogenic Src as demonstrated by translocation of endogenous ERK5 from the cytoplasm to nucleus and activation of an ERK5-dependent transcriptional reporter and that ERK5 activation is required for Src-mediated transformation. We also show that in Src-transformed cells inhibition of ERK1/2 signalling is not sufficient for reappearance of the actin cytoskeleton and that ERK5 activation contributes to cytoskeletal disruption by Src. Our results suggest that multiple MAP kinase pathways downstream of oncogenes participate in cytoskeletal alterations.

Key words: ERK5, ERK1/2, MAPK, Ras, Src, Cytoskeleton

This article has been cited by other articles:

				J. Park, C. Will, B. Martin, L. Gullotti, N. Friedrichs, R. Buettner, H. Schneider, S. Ludwig, and V. Wixler Deficiency in the LIM-only protein FHL2 impairs assembly of extracellular matrix proteins FASEB J, July 1, 2008; 22(7): 2508 - 2520. [Abstract] [Full Text] [PDF]

				M. Schramp, O. Ying, T. Y. Kim, and G. S. Martin ERK5 promotes Src-induced podosome formation by limiting Rho activation J. Cell Biol., June 30, 2008; 181(7): 1195 - 1210. [Abstract] [Full Text] [PDF]

				H. de Martimprey, J.-R. Bertrand, A. Fusco, M. Santoro, P. Couvreur, C. Vauthier, and C. Malvy siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma Nucleic Acids Res., January 17, 2008; 36(1): e2 - e2. [Abstract] [Full Text] [PDF]

				A. W. Truman, S. H. Millson, J. M. Nuttall, V. King, M. Mollapour, C. Prodromou, L. H. Pearl, and P. W. Piper Expressed in the Yeast Saccharomyces cerevisiae, Human ERK5 Is a Client of the Hsp90 Chaperone That Complements Loss of the Slt2p (Mpk1p) Cell Integrity Stress-Activated Protein Kinase Eukaryot. Cell, November 1, 2006; 5(11): 1914 - 1924. [Abstract] [Full Text] [PDF]

				R. E. Schweppe, T. H. Cheung, and N. G. Ahn Global Gene Expression Analysis of ERK5 and ERK1/2 Signaling Reveals a Role for HIF-1 in ERK5-mediated Responses J. Biol. Chem., July 28, 2006; 281(30): 20993 - 21003. [Abstract] [Full Text] [PDF]